Download presentation
Presentation is loading. Please wait.
Published byJeffry Watson Modified over 9 years ago
1
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
2
Classes of recommendations Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
3
Levels of evidence Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
4
Investigational algorithm for patients with coronary artery disease and diabetes mellitus Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
5
Definition, classification, and screening of diabetes and pre-diabetic glucose abnormalities Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
6
Criteria used for glucometabolic classification according to the WHO (1999) and ADA (1997 and 2003) (values are expressed as venous plasma glucose) Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
7
Aetiological classification of glycaemia disordersa a Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
8
Conversion factors between plasma and other vehicles for glucose values Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
9
Fasting and post-load glucose levels identify different individuals with asymptomatic diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
10
FINnish Diabetes Risk SCore (FINDRISC) to assess the 10 year risk of type 2 diabetes in adults Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
11
Epidemiology of diabetes, IGH, and cardiovascular risk Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
12
Age- and gender-specific prevalence of diabetes in 13 European population-based cohorts included in the DECODE study Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
13
Identification of subjects at high risk for CVD or diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
14
Summary of the findings of four lifestyle intervention studies that aimed at preventing type 2 diabetes in subjects with IGT Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
15
Treatment to reduce cardiovascular risk Lifestyle and comprehensive management Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
16
Mean efficacy of pharmacological treatment options in patients with type 2 diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
17
Percentage of patients achieving pre-defined intensive treatment targets in the Steno 2 study Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
18
Glycaemic targets for the care of patients with diabetes as recommended by various organizations Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
19
Potential downsides of pharmacological treatment modalities in patients with type 2 diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
20
Suggested policy for the selection of glucose- lowering therapy according to the glucometabolic situation Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
21
Treatment to reduce cardiovascular risk - Dyslipidaemia Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
22
Subgroups of patients with DM in the major secondary prevention trials with statins and the proportionate risk reduction in patients with and without diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
23
Treatment to reduce cardiovascular risk - Blood pressure Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
24
Treatment effects of antihypertensive drugs in comparison with placebo or less intensive treatment as reported in randomized clinical trials Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
25
Treatment effects expressed in hazard ratios (95% CI) in randomized clinical trials comparing different antihypertensive treatments in hypertensive patients with type 2 diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
26
Management of CVD - Coronary artery disease Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
27
Treatment options based on accumulated evidence Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
28
Recommended treatment targets for patients with diabetes and CAD Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
29
Diabetes and coronary revascularization Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
30
Trials addressing diabetes and revascularization for multivessel disease Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
31
Revascularization in diabetes patients with multivessel disease in the stent-era Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
32
Heart failure and diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
33
Arrhythmias: atrial fibrillation and sudden cardiac death Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
34
Peripheral vascular disease Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
35
Investigations of the peripheral circulation in diabetic patients Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
36
Stroke Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
37
Intensive care Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
38
Published trials on intensive insulin therapy in critical illness Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
39
Health economics and diabetes Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
40
Direct medical costs for patients with type 2 diabetes in eight European countries and percentage of healthcare expenditure in the respective countries (1998) Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:88-136
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.